Balyasny Asset Management’s Damora Therapeutics DMRA Stock Holding History
Bought
Maintained
Sold
Other funds holding DMRA
Balyasny Asset Management's DMRA Position: Q3 2026 in Review
Balyasny Asset Management reduced its Damora Therapeutics (DMRA) stake by 21% in Q3 2026, selling an estimated $7.24M and leaving 973,000 shares worth $20.7M. The position accounts for 0.02% of the portfolio, ranked #759.
Balyasny Asset Management first reported a position in DMRA in Q1 2026 and has held it in 3 quarters since. The position peaked at $37.5M in Q1 2026. 115 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.
- Balyasny Asset Management held 973,000 shares of Damora Therapeutics worth $20.7M as of Q3 2026.
- Balyasny Asset Management sold 256,127 Damora Therapeutics shares in Q3 2026, an estimated $7.24M.
- Damora Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q3 2026, its #759 holding.
- Balyasny Asset Management first reported a position in Damora Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Balyasny Asset Management's Damora Therapeutics position peaked at $37.5M in Q1 2026.
- 115 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.
Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.